Metabolic Syndrome in Mexican Women Survivors of Breast Cancer: A Pilot Study at a General Hospital

Medical Archives 02/2014; 68(1):19-21. DOI: 10.5455/medarh.2014.68.19-21
Source: PubMed


According to developed countries' studies, in breast cancer survivors there is a high prevalence of metabolic syndrome; however, in Mexico data is lacking about this issue.
To explore if metabolic syndrome occurs in Mexican women survivors of breast cancer.
At a second-level general hospital, women with breast cancer with a surviving > 2 years were studied. The analysis involved their demographic and anthropometric features, blood pressure measurement, time of surviving, besides fasting blood levels of lipids and glucose.
The sample consisted of 100 women; 42% were obese (body mass index > or = 30 kg/m2). The sample's mean age was 60 years with a mean surviving time of 6.5 years. Their mean glucose level was 122 mg/dL and triglycerides 202 mg/dL. There were 33% with blood pressure > or = 130/85mm Hg or diagnosis of hypertension. Fifty-seven percent had glucose > 99 mg/dL or diagnosis of diabetes mellitus, and 58% had triglycerides > 149 mg/dL. Metabolic syndrome occurred in 57% of obese women.
Our results suggest that metabolic syndrome occurs in more than 50% of obese Mexican women survivors of breast cancer.

Download full-text


Available from: carlos manuel ortiz-mendoza, Feb 21, 2014
  • Source
    • "Our study in western Iran , recently study [9] and also in eastern Iran [10] show that mean of age in women with breast cancer is around 45 to 50 years, but other recently studies [11] [12] , in northwest Iran [13] and in western Iran [14] show that mean of age is around 50 to 70 years. In center of Iran the mean was lower [15] . "
    [Show abstract] [Hide abstract]
    ABSTRACT: Objective:To investigate and compare the prognostic value of P53 and Ki67 markers with age and metastasis and survival in patients with breast cancer in Kermanshah, western Iran. Methods:In our study on 116 patients with breast cancer that all of them were women and kind of pathology was invasive ductal carcinoma and patients had Her2 positive. The expression of ki67 marker and p53 genes were determined by immunohistochemistry. Statistical analysis was performed with SPSS version IBM 19 and Disease free survival was calculated using the Kaplan-Meier method and log-rank test. Patients were followed up to 5 years. Results:The age mean of patients was 46.5±10.75.Of 116 patients, 23 patients (19.8%) had breast cancer with metastasis and 93(80.2%) without metastasis. expression of P53 (50%) in58 patients was positive and 58(50%) was negative. there is a statistically significant relationship between the p53 and metastasis (P<0.05), but no for Ki67. The over expression of p53 protein and Ki67 had no significant relationship with survival rate (P>0.05). Conclusions:The results showed that the Ki67 marker and P53 protein are important factors in the breast cancer patients with emphasis on therapeutic agents.
    Full-text · Article · Jun 2014